Equities

Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)60.98
  • Today's Change1.33 / 2.23%
  • Shares traded1.12m
  • 1 Year change+65.93%
  • Beta1.2922
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments336363741
Total Receivables, Net23423191
Total Inventory12810054
Prepaid expenses494540
Other current assets, total------
Total current assets746739926
Property, plant & equipment, net75768.79
Goodwill, net417409--
Intangibles, net473547--
Long term investments------
Note receivable - long term------
Other long term assets------
Total assets1,7331,8421,104
LIABILITIES
Accounts payable12181.54
Accrued expenses1009724
Notes payable/short-term debt000
Current portion long-term debt/capital leases01389
Other current liabilities, total0.963.251.75
Total current liabilities112131117
Total long term debt1,4991,493787
Total debt1,4991,506877
Deferred income tax------
Minority interest------
Other liabilities, total38483.07
Total liabilities1,6491,672907
SHAREHOLDERS EQUITY
Common stock0.130.140.14
Additional paid-in capital2.4127256
Retained earnings (accumulated deficit)91143(59)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(9.28)(0.92)(0.62)
Total equity84170197
Total liabilities & shareholders' equity1,7331,8421,104
Total common shares outstanding127135137
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.